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Abstract 
BACKGROUND: Very little is known about the eye movement performance (EMP) of children with 
Attention Deficit-Hyperactivity Disorder {ADHD), a syndrome involving attentional impairments, 
impulsivity, and typically, motor overactivity. Under achievement in reading and math has been shown to 
be associated with ADHD. Because ADHD children have been described as having slower response times, 
more topographical errors, and below age expected results on psychometric tests, we hypothesized that 
eye movement performance would also be below age expected. Since psycho stimulants reportedly 
decrease errors, variability, and response time with ADHD children, eye movement performance was 
sampled with and without their regularly prescribed medication. 
METHODS: 36 children age 8 to 13 with normal eyesight and hearing and who were taking 
psychostimulant medication for ADHD, were recruited for this study. The Developmental Eye Movement 
Test (DEM), Groffman Visual Tracing Test (GVTT), Peabody Picture Vocabulary Test (PPVT), and the 
Visagraph Eye Movement Analysis (VEMA), were administered to all subjects. Several months later 18 
original subjects were retested after not having taken their respective medication(s) for a minimum of 24 
hours. 
RESULTS: Mean DEM percentiles for the medicated ADHD group was: 44.18 vertical, 40.06 horizontal, 
44.12 ratio, and 49.35 for errors. Mean PPVT percentile was 60.38. Horizontal DEM subtest performance 
was significantly better for the 18 subjects while non-medicated. VEMA, GVTT, and PPVT performance did 
not significantly differ between medicated versus nonmedicated conditions for these same subjects. 
CONCLUSION: Based upon DEM results, Eye Movement Performance for the medicated ADHD group was 
slightly below normal. Above average mean PPVT auding vocabulary performance suggests that the 
reduced EMP was not due to reduced language ability. Surprisingly, horizontal subtest performance on the 
DEM was significantly better (p<0.01) while subjects were non-medicated. VEMA performance did not 
differ between the conditions. 
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ABSTRACT 
BACKGROUND: Very little is known about the eye movement performance 
(EMP) of children with Attention Deficit-Hyperactivity Disorder {ADHD), a 
syndrome involving attentional impairments, impulsivity, and typically, motor 
overactivity. Under achievement in reading and math has been shown to be 
associated with ADHD. Because ADHD children have been described as 
having slower response times, more topographical errors, and below age 
expected results on psychometric tests, we hypothesized that eye movement 
performance would also be below age expected. Since psycho stimulants 
reportedly decrease errors, variability, and response time with ADHD children, 
eye movement performance was sampled with and without their regularly 
prescribed medication. 
. 
METHODS: 36 children age 8 to 13 with normal eyesight and hearing and who 
were taking psychostimulant medication for ADHD, were recruited for this study. 
The Developmental Eye Movement Test (DEM), Groffman Visual Tracing Test 
(GVTT), Peabody Picture Vocabulary Test (PPVT), and the Visagraph Eye 
Movement Analysis (VEMA), were administered to all subjects. Several months 
later 18 original subjects were retested after not having taken their respective 
medication(s) for a minimum of 24 hours. 
RESULTS: Mean DEM percentiles for the medicated ADHD group was: 44.18 
vertical, 40.06 horizontal, 44.12 ratio, and 49.35 for errors. Mean PPVT 
percentile was 60.38. Horizontal DEM subtest performance was significantly 
better for the 18 subjects while non-medicated. VEMA, GVTT, and PPVT 
performance did not significantly differ between medicated versus non-
medicated conditions for these same subjects. 
CONCLUSION: Based upon DEM results, Eye Movement Performance for the 
medicated ADHD group was slightly below normal. Above average mean 
PPVT auding vocabulary performance suggests that the reduced EMP was not 
due to reduced language ability. Surprisingly, horizontal subtest performance 
on the DEM was significantly better (p<0.01) while subjects were non-
medicated. VEMA performance did not differ between the conditions. 
KEY WORDS: attention deficit disorder, saccades, fixations, eye movements, 
hyperactivity 
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INTRODUCTION 
There are ~~3.5 million American youngsters, or nearly 5% of those under 18" 1 
years old diagnosed with Attention Deficit Disorder with and without 
hyperactivity (ADD/ADHD). Attention Deficit Disorder is defined as a disorder of 
attention span, impulse control, motor activity and rule governed behavior 
beginning before the age of six or seven, persisting over time (6 months or 
more), pervasive (cross-situational though not necessarily uniform) and without 
obvious gross neurologic, sensory, motor or severe emotional impairment.2 
The diagnosis of ADHD stems from the American Psychiatric Association's 
~~Diagnostic and Statistical Manual of Mental Disorders (DSM-111-R)(appendix 1 ). 
Based on this knowledge of problems with attention, we were curious to find out 
whether ADD/ADHD affects children's eye movements, since previous research 
has shown that eye movements correlate with academic performance, 
especially reading.3 Since ADHD subjects were not differentiated from ADD 
subjects in this study, for the purpose of brevity in the remainder of th is paper, 
they will be referred to as ADD subjects. 
. 
Presently, very little is known about the eye-movement ability of ADD children. 
However, it is widely known that attentional ability is closely related to eye 
movement ability, but there has been little published data how children with 
attentional deficit disorders perform on standard clinical eye movement tasks. 
Motivation for this research is a desire to educate eye care practitioners about 
the oculomotor skills of ADD/ADHD children. 
The first goal of this investigation is to determine whether there are eye 
movement differences between ADD children and non-ADD children. The 
second question examines if there are potential eye movement differences 
between ADD children when medicated versus non-medicated. The final 
question asks how reliable are the clinical eye movement tests when ADD 
children are examined while medicated and non-medicated. 
Subjects 
Thirty-four school age children, ages eight to thirteen, were recru ited from within 
the greater metropolitan Portland, Oregon area for this study. This age range 
was selected based upon the normative parameters of the Developmental Eye 
Movement Test, Groffman Visual Tracings, and the Peabody Picture Vocabulary 
Test. Fliers, press releases, and referrals were utilized to identify the subjects. 
Prospective subject's parents contacted the researchers by phone and a ten 
minute screening interview was conducted to determine the child's eligibility. 
Participation in the study required that the subjects meet the following criteria: 
1. Diagnosis of Attention Deficit Disorder by a licensed 
medical doctor or psychologist. 
2. Age from eight to th irteen years old. 
3. English as a first language. 
4. Normal eyesight and hearing. 
5. Two one hour visits to one of Pacific University's Family 
Vision Centers. 
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Subjects (con't) 
Of the original 46 children who qualified for this study, 34 participated in the 
initial phase. Eighteen of the original 34 returned to complete the second and 
final phase. The average age of our 34 subjects was 10.2 years. Our sample of 
34 children included seven females (20%), and 27 males (80%). The average 
age of the 18 subject subset was 10.9 years. This sample included two females 
(11%) and 16 males (89%). The ethnicity of our sample was predominantly 
Caucasian. The socio-economic status of families in our study was not 
investigated. 
Grade level for subjects in our sample ranged from third to seventh grade, with 
a mean grade level of 4.8. Recent standardized academic achievement scores 
were obtained for each subject from their respective schools. Our subjects 
possessed a broad range of academic achievement; T.A.G. (talented and 
gifted) to learning disabled. The mean age equivalent of the subject's auding 
vocabulary was 11 years old as measured by the Peabody Picture Vocabulary 
Test. 
Of the 34 subjects who came in for the first visit, 27 subjects were on single 
psychoactive medications, four subjects were on multiple psycho-active 
medications, and three subjects were on alternative medications/treatments 
which included various vitamins, minerals, and amino acids. Fifty percent of the 
subjects were taking Ritalin at the time of their visit. (See chart below) 
p h syc oact1ve M d. r e 1ca 1ons T k 0 F tv· 't ( 34) a en n 1rs lSI: n= 
Name of Medication Number of Percentage 
Children of Children 
Methylphenidate hydro chloride (Ritalin) 17 50.0 
Dextro-amphetamine sulfate (Dexedrine) 5 . 14.7 
Imipramine hydrochloride (Tofranil) 3 8.8 
Pemoline (Cylert) 2 5.9 
*Multiple Medications 4 11.8 
**Alternative Medications 3 8.8 
*Multiple Med1cat1ons: 
Subject #1: Pemoline (Cylert), Clonidine hydrochloride, and Paxil; 
Subject #2: Zolaft and Methamphetamine hydrochloride (Desoxyn); 
Subject #3: Prozac and Bupropion hydrochloride (Wellbutrin); 
Subject #4: Clonadine and Zolaft 
**Alternative Medications!freatments: Kelp, Herbs, Spirulina, Nystatin powder, 
Niacinamide, Pyrdoxals phosphate, Theramins-M, Buffered Vitamin C, 
Magnesium Taurate, and various vitamins. 
METHODS 
This study was designed with two separate data gathering sessions. However, 
only about 18 of the participants (53%) returned for the second phase of data 
gathering. 
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METHODS (con't) 
The first phase required subjects to come in for testing while currently taking 
their prescribed medications. Subjects were instructed to take their last dosage 
of medication 2 to 4 hours prior, or to take their regularly scheduled dosage 
before their first appointment. Data for the first phase of testing was gathered 
from June to September 1995. 
The second phase required a return visit approximately 6 months after the first 
visit and the subject's parents were notified by the researchers to schedule a 
second visit. A requirement of the second visit was no ingestion of ADD 
medication(s) for at least 24 hours prior to testing. This requested time period 
without medication was required to eliminate the drugs effect within the blood 
plasma. The blood plasma t112 of the medications varied from about 2 hours for 
Ritalin and 7-8.6 hours for Cylert. Dexedrine, based on urinary acidification to a 
pH of <5.6, yields a plasma 1112 of 7-8 hours. Imipramine is listed as having a 
"long t112 life."4 Four of the subjects were on Selective Serotonin Reuptake 
Inhibitors (SSRI) medications. All SSRI's half-life include the active metabolite 
norfluoxetine, which is used in figuring plasma half-lites. The range of the 
SSRI's half-life used is 21-216 hours.5 
The same test battery that was given in the first phase was readministered in 
the second phase using the same protocols. However, during the second visit, 
subject's parents were asked to complete a questionnaire addressing the 
"Effectiveness of Medication" (appendix IV). 
With the exception of the P.P.V.T., the following tests were administered twice to 
each subject in both phases of the study (the Peabody was administered twice, 
once at the first session and again during the second); 
Developmental Eye Movement Test (D.E.M.) 
Groffman Visual Tracing Test (G.V.T.T.) 
Peabody Picture Vocabulary Test (P.P.V.T.) 
OberNisagraph Eye Movement Analysis (V.E.M.A.) 
For all testing, the following general protocols were observed: 
Subjects were comfortably seated next to a rectangular table in a well lit 
(fluorescent lighting) classroom at Pacific University College of Optometry. For 
most all subjects, a parent was seated adjacent, while the investigators sat 
facing the child throughout the testing battery. All the children were tested with 
their best visual correction (if needed). Each test was administered as faithfully 
as possible with the protocols specified in the respective test manuals. 
Brief descriptions of the tests are as follows: 
D.E.M.: 
The Developmental Eye Movement Test (D.E.M.) is an oculomotor test 
designed to assess saccadic-fixational eye movements. Tests A and 8 (two 
columns of vertically aligned numbers) represents a baseline measure of 
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METHODS (con't) 
visual-verbal response time or automaticity. Test C (16 rows of horizontally 
spaced numbers) primarily represents a measure of horizontal saccadic eye 
movements and fixation ability. For the horizontal portion of the test (Test C), 
any additions, omissions, transpositions, and substitutions that the subject may 
have made are taken into consideration and the score is accordingly adjusted 
or compensated. These adjustments result in "true time-scores." Furthermore, 
"the ratio of the horizontal test to the vertical test provides an index of the 
processing time in the horizontal dimension relative to the vertical". 6 
The D.E.M. is age normed from ages six to 13 years 11 months. Recommended 
standardized testing protocol was followed when administering the D.E.M.7 
G.V.T.T.: 
"The Groffman Visual Tracing Test (G.V.T.T.) is a test of self-generated ocular 
pursuits in which the patient is required to visually trace lines that are 
embedded in other curving, tangled lines." s It is a considered primarily a visuo-
spatial task which requires a minimal language ability but good figure ground 
perception. Age normed from seven to twelve, mean scores are based upon 
the speed and accuracy of the subject's response. · 
PPVT: 
The Peabody Picture Vocabulary Test (P.P.V.T.) represents a measure of 
auding vocabulary ability. The value measured is then extrapolated to a 
standard score intelligence quotient based upon the subject's age. The 
P.P.V.T. is normed for subjects aged 2 years 6 months to 40 years 11 months.9 
For this test, subjects are asked to listen carefully and identify a word given 
verbally by the examiner. Subjects were instructed to point to one of four 
pictures that corresponded to the word; or call out the number of the picture in 
the test booklet that matched the spoken word. As recommended in the test 
manual, each subject was informed that at some point during the testing their 
current vocabulary ability would be exceeded and that best guesses would be 
appropriate. 
OBERNISAGRAPH: 
The OberNisagraph Eye Movement Analysis Instrument (V.E.M.A.) measures 
eye position 60 times per second while a subject reads a standardized 100 
word passage. Information from infra-red sensors in the goggles is transmitted 
to a computer program which reconstructs and tabulates the eye movements. 
The Visagraph records the following information: fixatrons/1 00 words, 
regressions/100 words, directional attack, average span of recognition (words), 
average duration of fixation (seconds), reading rate with comprehension 
(words/minute), rate adjusted for rereading (words/minute), relative efficiency, 
grade level equivalent, and a cross correlation value between the right and left 
eyes. Reading comprehension is estimated for each passage by having the 
subject answer 10 standardized oral questions given by the examiner. These 
data are compared to Taylor eye movement normative data incorporated into 
the Visagraph software. Results are then displayed numerically and also 
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METHODS (con't) 
graphically. Thus, by evaluating these components an analysis is displayed by 
normed grade levels from grade one to grade 18 (college levei).10 
To choose an appropriate grade level reading passage for the Visagraph, 
subjects were asked what grade level they were currently in, and parents were 
asked if their child was reading at the appropriate grade level. Based on this 
information, subjects were asked to read aloud a sample passage to evaluate 
the appropriateness of the reading level demand for the test. Subjects were 
then asked 1 0 questions to see if they were able to comprehend what they had 
just read. If they read fluently and answered at least 7 of 1 0 questions correctly, 
that grade level demand was chosen for VEMA testing. However, if there was 
difficulty with comprehension or oral reading was not fluent, the reading 
demand level dropped down to a more appropriate level. 
Grade level demand of the Visagraph paragraphs used ranged from second to 
seventh grade level. The average grade level demand of the paragraph read 
by the subjects was 4.2 versus the subject's actual grade placement which 
averaged 4.8 (age 1 0 .5 years) . Overall, the subject's' read passages slightly 
below their actual grade level placement. 
To briefly recap the goals of this study, we posed three specific questions. 
1. Are there eye movement differences between ADD children in our sample 
and non-ADD children? 2. Are there potential eye movement differences 
between ADD children when medicated versus non-medicated? 3. If so, how 
reliable are our clinical eye movement tests with ADD children and how well do 
the tests correlate when the children are medicated versus non-medicated? 
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RESULTS 
QUESTION 1: 
Are there eye movement differences between ADD children and non-ADD 
children? 
DEVELOPMENTAL EYE MOVEMENT TEST RESULTS: 
MEDICATED CONDITION- All Participants (n=34) 
MEAN STANDARD DEVIATION 
Vertical S.S. 96.74 19.31 
Vertical% 44.18 35.08 • 
Horizontal S.S. 94.88 17.66 
Horizontal % 40.06 31.79 
Ratio S.S. 97.24 13.90 
Ratio% 44.12 29.86 
Errors S.S. 99.59 15.51 
Errors% 49.35 30.54 
• [% =percentile, S.S. =Standard Score]T able 1: The normative means for the OEM Test are 
1 00 for standard score and 50 for percentile. Means for our ADD sample were slightly below that 
reported for the normative population. The horizontal subtest yielded the lowest means for the 
ADD group. 
OEM PERFORMANCE COMPARED TO THE HISTORICAL CONTROL GROUP: (n=34) 
Sample Historical t- Value Probability 
Mean Control (2-tailed) 
Group 
Medicated Vertical Time % 43.92 50 -1.07 0.2922 
Medicated Vertical Standard Scores 94.58 100 -1.43 0.1622 
Medicated Horizontal Time % 39.83 50 -1.98 0.0562 
Medicated Horizontal Standard Scores 92.74 100 -2.03 0.0498 
Medicated Ratio % 43.72 50 -1.30 0.2038 
Medicated Ratio Standard Scores 94.92 100' -1.57 0.1245 
Medicated Errors % 48.83 50 -0.24 0.8154 
Medicated Errors Standard Scores 97.25 100 -0.80 0.4284 
Table 2: A t-test companson of the med1cated ADD group to the h1stoncal control1nd1cated that only the 
horizontal subtest standard score mean was significantly different from the population mean (p<0.5). The 
horizontal subtest mean percentile fell just short of being significant. 
GROFFMAN RESULTS: 
MEDICATED MEANS (n=34) 
A.E. S.D. Z-Score % 
Test A 7.98 3.51 8.43 >99.9 
Test B 9.77 2.56 16.3 >99.9 
• [ A.E. =Age Equivalent In Years, S.D.= Standard Deviation,%= Percentile] 
Table 3: The Groffman Visual tracing Test yielded A. E. scores below the mean (10.2 year) 
expected age for the ADD group. The A. E. and Z-score increased from Test A (given as the first 
trial) to Test B (given as the second trial), revealing that there was a practice effect for this clinical 
test. The extraordinarily high percentile score indicated a dramatic ceiling effect for this test. 
13 
RESULTS (cont) 
VEMA MEANS (Second Trials)* (n=34) 
Mean Expected Mean Based on 
T avlor Norms 
Fixations 171.65 132.24 
Span of Recognition 0.68 0.76 
Regressions 48.41 28.76 
Duration of Fixation 0.31 0.27 
Rate Adjusted for RereadinQ 173.24 . 168.29 
Relative Efficiency 0.87 1.07 
Grade Level 3.89 **4.7 
Comprehension 80.9 *** 
[*Two separate VEMA measurements were taken at each session. Only results of the second 
measurement are shown here because previous research has shown rel!ability to be higher for 
the second VEMA measurement.11 
[**Grade level derived from Relative Efficiency Score] 
[*** No expected mean based on Taylor norms available] 
Table 4: For every single category of the VEMA, the ADD subjects did worse than expected 
based upon the Taylor norms. 
QUESTION 2: 
Are there potential eye movement differences or other differences in ADD 
children when in the medicated versus non-medicated states? 
DEVELOPMENTAL EYE MOVEMENT TEST RESULTS: MEDICATED CONDITION AND NON-
MEDICATED CONDITION (n=18) 
Phase One· Medicated Phase Two· Non-medicated 
MEAN S.D. MEAN S.D. 
Vertical S.S. 95.89 15.71 100.06 16.35 
Vertical% 42.83 31.37 47.17 ·32.14 
Horizontal S.S. 93.22 "13.18 98.89 14.40 
Horizontal % 36.72 26.76 47.22 30.93 
Ratio S.S. 96.56 14.90 96.44 12.15 
Ratio% 42.50 31.17 41.67 25.90 
Errors S.S. 98.67 11.01 105.28 10.26 
Errors% 48.61 24.00 61.33 19.42 
Table 1: Comparing the 18 subjects while 1n the medicated and unmed1cated states revealed that 
the subjects did better while in the non-medicated state in all areas except for the ratio scores. 
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RESULTS (cent) 
DEM PERFORMANCE COMPARED TO HISTORICAL CONTROL GROUP (n=18) 
Sample Pop. t-Value Probability 
Mean Mean (2-tailed) 
Non-Medicated Vertical Time% 47.17 50 -0.37 0.7130 
Non-Medicated Vertical SS 100.06 100 0.01 0.9887 
Non-Medicated Horizontal Time % 47.22 50 -0.38 0.7079 
-
Non-Medicated Horizontal SS 98.89 100 -0.33 0.7473 
Non-Medicated Ratio% 44.67 50 -1.37 0.1900 
Non-Medicated Ratio SS 96.44 100 -1.24 0.2312 
Non-Medicated Errors % 61.33 50 2.48 0.0241* 
Non-Medicated Errors SS 105.28 100 2.13 0.0434* 
Medicated Vertical Time % 42.51 50 -1.27 0.2740 
Medicated Vertical SS 92.10 100 -1.56 0.1359 
Medicated Horizontal Time % 36.64 50 -2.36 0.0294** 
Medicated Horizontal SS 89.53 100 -2.23 0.0381 ** 
Medicated Ratio % 41.95 50 -1.22 0.2390 
Medicated Ratio SS 92.46 100 -1.45 0.1632 
Medicated Errors % 47.75 50 -0.44 0.6668 
Medicated Errors SS 94.56 100 -1.14 0.2677 
. [ * = better than normative population (p<0.5); **=worse than normat1ve population (p<0.5)) 
TABLE 2: Eye movement performance for subjects both medicated and non-medicated were 
compared to published normative data provided with the DEM test. In general, medicated 
subjects performed worse than the published means, especially on the horizontal subtest. 
Horizontal subtest performance while medicated was significantly worse than that expected for 
the historical control group. When non-medicated, the 18 subjects in phase two did better, nearly 
as well as the normative population. In the case of errors, they performed significantly better than 
the historical control group. 
"'**Bonferoni adjustment - suggestive but not statistically significant 
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RESULTS (cent) 
DEVELOPMENTAL EYE MOVEMENT TEST RESULTS: 
MEDICATED VERSUS NON-MEDICATED CONDITIONS (rWO TAILED T-TESTI (n=18) 
MeanX-Y Paired Probability 
T- Value (2 Tailed) 
SS Mean Vertical Time Medicated vs. SS Mean -4.17 -1.56 0.1382 
Vertical Time Non-Medicated 
Medicated Vertical Time% vs. Non-Medicated -4.33 -0.76 0.4587 
Vertical Time % 
SS Mean Horizontal Time Medicated vs. SS Mean -5.67 -2.94 0.0091 * 
Horizontal Time Non-Medicated 
Medicated Horizontal Time % vs. Non-Medicated -10.50 -2.89 0.01 02* 
Horizontal Time % 
SS Medicated Ratio vs. SS Non-Medicated Ratio 0.11 0.03 0.9772 
Medicated Ratio % vs. Non-Medicated Ratio % 0.83 0.11 0.9148 
SS Medicated Errors vs. SS Non-Medicated -6.61 -2.23 0.3950 
Errors 
Medicated Errors % vs. Non-Medicated Errors % -11.06 -1.91 0.0736 
[SS =Standard Score; %=percentile (p<0.5)] 
[*=significant value] • 
Table 3: The means for the Developmental Eye Movement test were compared using a two tailed 
T-test. Horizontal subtests differed significantly between the medicated and non-medicated 
conditions, using both SS and% values. When non-medicated, the subjects took less time and 
called out the numbers more rapidly. The means of the vertical time ratio and errors did not differ 
significantly, although there was a trend of better performance in the non-medicated condition. 
GROFFMAN RESULTS: 
MEDICATED AND NON-MEDICATED MEANS (n=18) 
Medicated Non-medicated 
A. E. Std. Dev. Z-Score % A. E. Std. Dev. Z-Score % 
TestA 8.36 3.61 10.26 >99 9.6 3.22 -1.01 16 
Test B 9.68 3.07 16.54 >99 10.28 3.06 1.03 84 
[*A.E.=Age Equ1valent, Std. Dev.=Standard Dev1at1on, %=percentile] 
Table 4: The mean age for the 18 subjects was 10.3 years in phase I, and 10.9 in phase II. Test A 
Groffman mean AE score improved from 8.4 years medicated to 9.6 years non-medicated. AE 
scores for test B similarly increased from 9.7 years medicated to 10.3 years non-medicated. 
Performance improved from Test A (given as the first trial) to Test B (given as the second trial) in 
both the medicated and non-medicated states, again revealing a large practice effect. The Z-
score and percentile means of test A and test B could not be meaningfully analyzed because of 
the apparent ceiling effect seen in this group with the Groffman test. 
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GROFFMAN TWO TAILED T-TEST (n=18) 
Mean X-V Paired T- Value Probabilitv (2 Tailed) 
Medicated total points (1st run) -5.11 -1.78 0.0924 
vs. Non-Medicated total points 
(1st run) 
Medicated total points (2nd run) -4.67 -1.72 0.1031 
vs. Non-Medicated total points 
(2nd run) 
Medicated Age Equivalent (1st -1.25 -1.63 0.1205 
run) vs. Non-Medicated Age 
Equivalent (1st run) . 
Medicated Age Equivalent (2nd -0.60 -0.90 0.3780 
run) vs. Non-Medicated Age 
Equivalent (2nd run) 
Medicated Z-score (1st run) vs. 10.71 3.84 0.0012 
Non-Medicated Z-score (1st run) 
Medicated Z-score (2nd run) vs. 15.51 6.06 <0.0001 
Non-Medicated Z-score (2nd run) 
Table 5: Th1s table 1nd1cates that when the means were compared between the two groups, 
performance did not differ significantly. Only the Z-scores were found to be significant both for 
the medicated first run vs. non-medicated first run and the medicated second run vs. non-
medicated second run. However, the magnitude of these values due to ceiling effect makes this 
comparison meaningless. 
VEMA 1st TRIALS- TWO TAILED T- TEST (n=18) 
Mean X-V Paired T- Value Probability 
(2 Tailed) 
Medicated Fixations** vs. Non-Medicated 51.94 1.78 0.0923 
Fixations 
Medicated Span of Recognition vs. Non- -0.05 -0.75 0.4629 
Medicated Soan of Recoanition 
Medicated Regressions vs. Non- 26.83 2.69 0.0155* 
Medicated Regressions 
Medicated Duration of Fixation vs. Non- 0.03 1.17 0.2585 
Medicated Duration of Fixation 
Medicated Grade/Level vs. Non- -0.64 -0.76 0.4588 
Medicated Grade/Level 
Medicated Comprehension vs. Non- -0.28 -0.53 0.6020 
Medicated Comprehension 
[*=significant value; **= fixations/1 00 words] 
TABLE 6: The VEMA computerized eye movement assessment was administered to each of the 
18 subjects a total of four times. During the first phase, two separate VEMA measurement 
samples were taken. This procedure was repeated for phase II. This table compares the first 
sample on the first visit and the first sample on the second visit. Results of this comparison 
indicated that only regressions differed significantly between the medicated and non-medicated 
conditions (p<0.5). Significantly more regressions were made while medicated than non-
medicated. Fixations, span of recognition, duration of fixation, measured grade level, and 
comprehension did not differ between the two conditions. 
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VEMA 2nd TRIALS- TWO TAILED T-TEST 
(n=18} MeanX-Y Paired T- Value Probability 
(2 Tailed) 
Medicated Fixations vs. Non-Medicated -20.89 ·0.94 0.3602 
Fixations 
Medicated Span of Recognition vs. 0.06 1.06 0.3053 
Non-Medicated Soan of Recoanition 
Medicated Regressions vs. Non- 6.67 0.76 0.4589 
Medicated Rearessions 
Medicated Duration of Fixation vs. Non- 0.01 0.89 0.3862 
Medicated Duration of Fixation 
Medicated Grade/Level vs. Non- 0.40 0.50 0.6248 
Medicated Grade/Level 
Medicated Comprehension vs. Non- -0.06 -0.12 0.9054 
Medicated Comprehension 
TABLE 7: This table compares the second VEMA measurement from phase I to the second 
VEMA measurement from phase II. VEMA results for the second measurement from each phase 
comparing medicated versus non-medicated conditions indicated that there were no significant 
differences in between the conditions for either fixations, span of recognition, duration of fixation, 
extrapolated grade level, or comprehension. 
PEABODY PICTURE VOCABULARY TEST: 
All Participants: 
Medicated Group Means (n=34) 
s.s. Std. % Std. Age Std. 
Dev. Dev. Equivalent Dev. 
104.71 18.76 60.38 27.26 10.87 3.02 
TABLE 8: Shows that the mean SS and% for all34 med1cated subjects was above average. 
Phase One: Phase Two: 
Medicated Group Means (n=18) Non-Medicated Group Means n=18) 
S.S. Std. % Std. A. E. Std. S.S. Std. 0/o Std. A. E. Std. 
Dev. Dev. Dev Dev. Dev. Dev. 
101.9 22.2 57.0 31.8 10.6 3.4 105.4 15.0 61.7 30.8 11.7 2.9 
Table 9: The means of both medicated (n=18} and non-medicated (n=18) standard score and 
percentiles were slightly above that expected for the historical control group. However, non-
medicated standard score, percentile, and age equivalent means were higher than when 
medicated. The subject's chronological age ranged from 8 to 13 years. Mean A. E. for the 18 
medicated subjects was 10.6 years and 11.7 years when non-medicated. This reflects an A.E. 
increase of 1.1 years. Chronological age differed by 4.5 months between the two conditions. 
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QUESTION 3: 
How reliable are clinical eye movement tests with ADD children and how well 
did they compare when the children were medicated versus non-medicated? 
CORRELATION COEFFICIENT· 
Medicated 1st Medicated 1st Trial Non-Medicated 1st 
Trial vs. Medicated vs. Medicated Trial vs. Non-
2nd Trial 2nd Trial Medicated 2nd Trial 
(n=34) (n-18) ln-18) 
OEM Vertical SS 0.92 0.80 0.93 
OEM Vertical Time% 0.77 0.77 0.81 
OEM Horizontal SS 0.90 0.79 0.94 
OEM Horizontal Time% 0.75 0.75 0.86 
OEM Ratio SS 0.29 -0.19 0.77 
OEM Ratio% 0.38 0.04 0.38 
OEM Errors SS 0.67 0.27 0.92 
OEM Errors% 0.85 0.24 0.85 
Groffman Ave. (Z-score) 0.76 0.80 0.65 
VEMA Fixations 0.56 0.45 0.45 
VEMA Span of 0.39 0.79 0.75 
Recognition . 
VEMA Regressions 0.40 0.20 0.29 
VEMA Duration of 0.88 0.65 0.47 
Fixation 
VEMA Grade Level 0.62 0.90 0.71 
VEMA Comprehension 0.74 0.71 0.44 
VEMA Rate Adjusted for 0.44 0.91 0.83 
Rereadinq 
Table 1: For the 34 medicated subjects, the OEM correlation was moderate to high with the 
vertical standard score (0.92) and horizontal standard score (0.90). Repeatability of the ratio 
standard score was poor with a correlation of only 0.29. Reliability between Groffman versions A 
and 8 was 0.76. VEMA correlations overall had a reliability less than OEM and the Groffman tests 
with a range from 0.88 (duration of fixation) to 0.39 (span of recognition). 
The smaller medicated sub-set group (n=18), yielded similar but lower patterns of correlations as 
did the larger medicated group, with four exceptions: Groffman, VEMA span of recognition, 
grade level, and rate. The OEM correlations ranged from 0.80 (vertical standard scores) to -0.19 
(ratio standard scores). The Groffman had a moderately high correlation between test A and test 
B of 0.80. VEMA correlations ranged from 0.20 to 0.91 . 
Non-medicated, the smaller group (n=18) had a similar pattern of moderate to high correlations on 
OEM subtests. The OEM correlations ranged from a high of 0.93 (vertical standard scores) to a 
low of 0.38 (ratio percentage). The Groffman correlation was shown to be moderate (0.65). 
VEMA correlations were very similar medicated and non-medicated. 
Although the apparent trend was higher reliability while non-medicated for most all subtests, 
statistical comparison of reliability coefficients medicated versus non-medicated indicated that 
only VEMA reading rate differed significantly between the two conditions. 
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PEABODY PICTURE VOCABULARY TEST CORRELATION COEFFICIENT: (n=13) 
Correlation 
Medicated Standard Score vs. Non-Medicated Standard Score 0.23 
Medicated Percentile vs. Non-Medicated Percentile 0.59 
Medicated Age Equivalent vs. Non-Medicated Age Equivalent 0.63 
Table 2: The highest PPVT correlation was seen w1th the age equ1valent score, wh1le the lowest 
correlation was found with the standard score. The percentile showed moderate correlation. 
These P.P.V.T. correlations represent only 13 subjects as a result of misplaced scores. 
GROFFMAN MEDICATED CORRELATION COEFFICIENT· 
(n=34) Correlation Coefficient 
Test A Age Equivalent vs. Test B Age Equivalent 0.60 
TestA Z -Score vs. Test B Z -Score 0.76 
Table 3: Moderate correlation was found between the Groffman age equivalent and Z-Score 
between test A and test B. 
GROFFMAN MEDICATED AND NON-MEDICATED CORRELATION COEFFICIENT: (n=18) 
Correlation Coefficient 
Test A Age Equivalent Medicated vs. 0.70 
Test B Age Equivalent Medicated . 
Test A Z-Score Medicated vs. Test B Z-Score Medicated 0.80 
Test A Age Equivalent Non-Medicated vs. 0.91 
Test B Age Equivalent Non-Medicated 
Test A Z-Score Non-Medicated vs. 0.65 
Test B Z-Score Non-Medicated 
Table 4: For the medicated state, there was moderate correlation between age equivalence for 
test A vs. Test B, while the Z-score registered a moderate to high value. Conversely, the non-
medicated state revealed a high correlation between test A vs. Test B of the age equivalent. The 
non-medicated Z-score showed a low correlation. 
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This study was centered around three questions: 
The first question examined if there were eye movement differences between 
ADD children and non-ADD children. The trend was for poorer eye movement 
performance with all the clinical eye movement tests, however, few of these 
mean differences were signficant. Significant differences were seen on the 
horizontal subtest of the OEM, with ADD subjects performing worse than the 
historical normative control group. 
From our data it is obvious that not all ADD children demonstrate poor eye 
movement performance. The ADD children in this stupy spanned a broad 
range of eye movement performance and academic ability (from talented and 
gifted to learning disabled). For the clinical eye movement measures that were 
selected, the mean standard deviations were very large which may have 
obscured poor performance by a subgroup of ADD subjects. Therefore, looking 
only at mean data may not reveal the presence of an ADD subgroup with poor 
eye movements. Future analyses will examine whether the majority of our 
subjects performed slightly below expected, or if there exists a small subgroup 
of individuals whose eye movements were far worse than that of the other 
subjects. 
If the horizontal subtest of the OEM differentiated ADD subjects from non-ADD 
subjects, why was that difference not seen with the GVTT and the VEMA 
measures? Although the VEMA indicated poorer mean eye movement 
performance by ADD children in nearly every category, it was not possible to 
statistically compare the performance of our ADD subjects with those of the 
VEMA normative group given the limited VEMA normative data available. 
Based upon GVTT results, eye movement skills were less than expected. 
These results need to be interpreted with caution given the dramatic test ceiling 
effect seen with these subjects. Alternatively, both the VEMA and GVTT may 
sample different eye movement sub-skills than the horizontal subtest of the 
OEM. The GVTT reportedly measures "self-generated pursuit eye movements," 
VEMA measures eye movement efficiency during reading (with heavy linguistic 
processing), whereas the horizontal subtest of the OEM is a saccadic-fixation 
task with a limited linguistic demand. 
The second question investigated if there were potential eye movement 
differences (and PPVT differences) in ADD children when medicated versus 
non-medicated. For the 18 subjects who were tested both medicated and non-
medicated, the mean OEM horizontal standard score and percentile was 
significantly worse when medicated. A comparison of this medicated subgroup 
to the historical control group indicated that mean horizontal OEM subtest 
performance was significantly worse than the historical control group. When 
non-medicated however, mean performance for these same individuals was not 
significantly different from that of the historical control group. In other words, 
this subset of ADD subjects demonstrated a deficit on the horizontal subtest of 
OEM only when medicated. Other OEM subtests, PPVT, VEMA, and Groffman 
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values did not yield significant differences when medicated versus non-
medicated. There were also no significant differences in PPVT results 
medicated versus non-medicated. 
For both questions one and two, the horizontal subtest of the OEM was the only 
clinical test to detect significant differences. Why didn't other OEM subtests 
detect these differences? Is the horizontal subtest a more sensitive eye 
movement measure than the other subtests? 
The vertical subtest of the OEM is described by the test authors 12 as a measure 
of visual-verbal response time, or automaticity. The vertical subtest is said to 
tap different neurological skills than those needed for the horizontal subtest. If 
the OEM vertical subtest samples automaticity and language ability, it is not 
unreasonable to expect that ADD individuals would not show differences in 
rapid naming ability as compared to non-ADD children. Further, ADD 
medications would not be expected to alter visual-verbal performance. 
There are several possible explanations for why there were no significant 
differences in mean horizontal/vertical subtest ratios medicated versus non-
medicated. Lack of significant differences in the ratio score may be due to the 
inherent variability of the score itself .13 Because the ratio is a derived score that 
amplifies the variability of two subtests from which it is calculated, it can not 
reliably detect subtle differences in performance. As reported by the test 
authors 14 the intrasubject test-retest reliability of the ratio score was only 0.57. 
Other investigators have reported even lower reliability co-efficients with 
children15. Similarly, the test authors also reported a large amount of variability 
in the normative error findings, so DEM error performance is not a reliable 
developmental measure.16 
An alternative explanation may be that horizontal OEM differences were due to 
chance or that they reflect increased maturation betwe'en test sessions. It is 
important to keep in mind that at the first testing session all subjects were 
medicated. Eighteen subjects returned for the second non-medicated testing 
session. These sessions were separated by a mean of 4.5 months, (range of 2 
to 6 months). This time interval may reflect a period of increased maturation, 
and perhaps better eye movement performance based on development alone. 
DEM horizontal age equivalent scores would argue against this explanation. 
Although the sessions were separated by a mean of 4.5 months, subject's 
mean horizontal subtest age equivalent performance increased from 9.72 years 
to 10.74 years from the first to the second session. This age equivalent 
improvement was much larger than that expected from the intersession interval 
alone. 
The vertical subtest of the DEM indicated no differences between medicated 
and non-medicated conditions. This indicates that it wasn't a basic language 
processing problem causing the difference in eye movements nor was it an 
automaticity or visual verbal response type of problem. 
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From our findings there was no clear indication of improved eye movement 
performance while they were taking their regularly prescribed medication(s). 
Stated another way, eye movement performance was not significantly improved 
by the ADD medications. In fact, our results showed the reverse, improved 
overall eye movement performance when non-medicated. 
The final question asked how reliable were the tests when the ADD children 
were medicated versus non-medicated. Except for VEMA reading rate, there 
were no differences in test reliability between conditions. Although the general 
trend was greater reliability in the non-medicated state, surprisingly, the only 
significant medicated versus non-medicated reliability difference found was 
opposite to this overall trend. VEMA reading rate reliability was significantly 
better when medicated (r=0.91 vs 0.83). It should be pointed out that better 
readers usually demonstrate more variability in their reading rates than do 
retarded readers because good readers are better able to adapt to the 
demands of the text. 
A review of ADD literature suggests that its effects are not entirely isolated only 
to attentional abilities. Previous investigations have associated ADD with 
central nervous system disorders. For example, ADD individuals can manifest 
gross and fine motor control delays (affecting 50% of ADD children), 
developmental delays, obsessive-compulsive disorder.s (OCD), and TIC 
Syndromes. Approximately 20% of children with ADD have Tourette's although 
40-60% of children with Tourette's have ADD.17 
Since CNS disorders are known to be related to attentional deficits, we theorize 
that not only do the subject's CNS psychotropic and Selective Serotonin 
Reuptake Inhibition (SSRI) medications influence specific target areas of the 
brain, but there is also an antagonistic effect on other neurological systems. In 
fact, poor eye movements may be a representation of decreased chemically 
induced neuronal innervation to specific cranial nerves, thereby interfering with 
the fluidity of ocular motility. 
Confirmation or disproval of this theory may require a randomized prospective 
crossover study, where non-ADD children would be administered a temporary 
regimen of the aforementioned psychotropic medications. Once the 
medications have reached proper blood plasma levels, the testing battery used 
for this study could be imposed. Pre and post analysis of medicated versus 
non-medicated eye movement performance results would then be compared 
with the results from children diagnosed with attentional deficit disorders. 
Future studies may provide a better understanding of the potential relationship 
between ADD medications and ocular motility. 
Future studies should also be directed at exploring alternative treatment 
methods that have been reported to be effective with ADD. These methods 
include dietary intervention including megavitamins and mineral supplements, 
anti-motion sickness medications, candida yeast, EEG biofeedback, applied 
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kinesiology, and vision therapy. To date, there have Been few rigorous 
scientific studies to substantiate claims for these therapies.1B 
Symptomology, severity, academic performance, and interpersonal 
relationships are so variable in this population that we feel there is no perfect 
treatment modality ... yet. So how do we best treat this population? It is 
essential that professionals familiarize themselves with the challenges that 
ADD presents, and prepare accordingly, keeping in mind that they are all 
special individuals--but diverse as a group. Further studies should be 
undertaken because the condition is so epidemic, and so many questions 
remain to be answered. 
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APPENDIX A 
ATTENTION DEFICIT HYPERACTIVITY DISORDER: DIAGNOSTIC 
CRITERIA 
ADHD is defined when exhibiting at least 8 of 14 specific behaviors for a period 
longer than 6 months and that its appearance presented before age seven. 
However, attentional deficit disorder does not require hyperactivity, in fact, up to 
30% of children with ADD are not hyperactive. 
The behaviors are as follows: 
1. Often fidgets with hands or feet or squirms in seat (in adolescents, maybe 
limited to subjective feeling of restlessness). 
2. Has difficulty remaining seated when required to do so. 
3. Is easily distracted by extraneous stimuli. 
4. Has difficulty awaiting turn in games or group situations. 
5. Often blurts out answers to questions before they have been completed. 
6. Has difficulty following through on instructions from others (not due to 
oppositional behavior or failure of comprehension) (e.g., fails to finish 
chores) 
7. Has difficulty sustaining attention in tasks or play activities. 
8. Often shifts from one uncompleted activity to another. 
9. Has difficulty playing quietly. 
1 0. Often talks excessively. 
11. Often interrupts or intrudes on others (e.g., butts into other children's 
games). 
12. Often does not seem to listen to what is being said to him or her. 
13. Often loses things necessary for tasks or activities at school or at home 
(e.g., toys, pencils, books, assignments). 
14. Often engages in physically dangerous activities without considering 
possible consequences (not for the purpose of thrill seeking) (e.g., runs 
into street without looking). 
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PRE- TEST QUESTIONS 
Parent's 
Name: Phone: 
---------------------------- -------------
Address: -----------------------------~--------------
Child's 
Name: DOS: Age: 
-------------------------- ---------- ----
Prenatal Complications: Yes No 
If yes: _________________________________________ _ 
Were there any complications during birth: Yes No 
If yes: _________________________________________ _ 
Any significant trauma to the head: Yes No 
If yes: _________________________________________ _ 
High Fever: Yes No 
If yes: _________________________________________ _ 
Loss of Consciousness: Yes No 
If yes: __________________________ ~---------------
Is The Child On Any Medications: Yes No 
Name of M ed i cation: ____________________________ _ 
D osage: _________ .. x" Ida y ________ Effect iven es s : ______ _ 
What Age Did They Begin With The Medication?: 
School History: ______________________________________ _ 
Involved with Chapter One or LAC: Yes No 
Currently Receiving Special Education In School: Yes No 
Learning Dis ab i I iti es (type): ____________________________ _ 
Diagnosed as ADD: Yes No 
By Whom: _________________ When ________________ _ 
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EYE MOVEMENT ASSESSMENT- SECOND VISIT 
DATE: ___________________________ _ 
CHILD'S 
NAME: 
----------------------------------------------
MEDICATION HISTORY: 
Regular dosage and time of day taken: _ _ 
As of today's visit, how many hours has it been since your child has 
taken their last dosage: ________________________________ _ 
How long have they been taking their medication(s): ______ _ 
Has the dose been changed since your last visit with us: 
If so, pi ease explain: ________________________________ _ 
In addition to the ADD/ADHD medications currently being taken, are 
there any other prescribed or over the counter medications being 
taken: ______________________________________________ _ 
Have you noticed any behavioral changes while on their respective 
medications. For example: Ability to stay on regular tasks, complete 
assignments at school, maintaining their grades, 
etc: ________________________________________________ _ 
Is your son/ daughter taking their medication(s) during the; 
a. weekends: . If so, is it the same dosage regimen 
that they receive during the school week? _ _ _____ ~---
b. summers: . If so, is it the same dosage regimen 
that they receive during the school year? _____________ _ 
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EFFECTIVENESS OF MEDICATION-SECOND VISIT 
This scale is to measure the difference between the medicated vs. 
Non-medicated state (5=Most difference; 1 =Least difference; O=Has 
not been a problem prior to medication) 
Academic Performance: 5 4 3 2 1 0 
Behavior at home and the 5 4 3 2 1 0 
ability to get along with family 
members: 
Ability to stay on task at 5 4 3 2 1 0 
home with school work: 
. 
Ability to stay on task at 5 4 3 2 1 0 
school with school work: 
Ability to get along with 5 4 3 2 1 0 
peers: 
I mpulsi vity/d ist racti bil ity: 5 4 3 2 1 0 
Regular sleeping cycles: 5 4 3 2 1 0 
Personal organization: 5 4 3 2 1 0 
(i.e. not losing items, etc.) 
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